Cargando…

Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response

BACKGROUND: High plasma osteopontin (OPN) has been linked to tumour hypoxia, metastasis, and poor prognosis. This study aims to assess whether plasma osteopontin was a biomarker of increasing progression within prostate cancer (PCa) prognostic groups and whether it reflected treatment response to lo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thoms, J W, Dal Pra, A, Anborgh, P H, Christensen, E, Fleshner, N, Menard, C, Chadwick, K, Milosevic, M, Catton, C, Pintilie, M, Chambers, A F, Bristow, R G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425969/ https://www.ncbi.nlm.nih.gov/pubmed/22871886 http://dx.doi.org/10.1038/bjc.2012.345

Ejemplares similares

Osteopontin is a marker for cancer aggressiveness and patient survival
por: Weber, G F, et al.
Publicado: (2010)

Nuclear osteopontin-c is a prognostic breast cancer marker
por: Zduniak, K, et al.
Publicado: (2015)

Expression of Osteopontin in oesophageal squamous cell carcinoma
por: Kita, Y, et al.
Publicado: (2006)

Expression of osteopontin coregulators in primary colorectal cancer and associated liver metastases
por: Mole, D J, et al.
Publicado: (2011)

Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer
por: Boldrini, L, et al.
Publicado: (2005)

FTIR-based spectroscopic analysis in the identification of clinically aggressive prostate cancer
por: Baker, M J, et al.
Publicado: (2008)

Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error
por: Shipitsin, M, et al.
Publicado: (2014)

The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer
por: Ragnum, H B, et al.
Publicado: (2015)

Wnt–β-catenin–Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer
por: Ravindranath, A, et al.
Publicado: (2011)

Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma
por: Sim, S H, et al.
Publicado: (2012)

Suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels
por: Rittling, S R, et al.
Publicado: (2014)

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer
por: Ihnen, M, et al.
Publicado: (2010)

Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease
por: Darby, S, et al.
Publicado: (2009)

Role of the metastasis-promoting protein osteopontin in the tumour microenvironment
por: Anborgh, Pieter H, et al.
Publicado: (2010)

Epstein-Barr virus as a marker of biological aggressiveness in breast cancer
por: Mazouni, C, et al.
Publicado: (2011)

Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis
por: Walsh, N, et al.
Publicado: (2010)

Testosterone regulates cell proliferation in aggressive fibromatosis (desmoid tumour)
por: Hong, H, et al.
Publicado: (2011)

FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancer
por: Cimino, Y, et al.
Publicado: (2012)

Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate
por: Elkahwaji, J E, et al.
Publicado: (2009)

Low ANXA10 expression is associated with disease aggressiveness in bladder cancer
por: Munksgaard, P P, et al.
Publicado: (2011)

Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype
por: Ameri, K, et al.
Publicado: (2010)

A putative OTU domain-containing protein 1 deubiquitinating enzyme is differentially expressed in thyroid cancer and identifies less-aggressive tumours
por: Carneiro, A P, et al.
Publicado: (2014)

PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness
por: Molleví, D G, et al.
Publicado: (2008)

Elevated expression of myosin X in tumours contributes to breast cancer aggressiveness and metastasis
por: Cao, R, et al.
Publicado: (2014)

Cadherin-1 and cadherin-3 cooperation determines the aggressiveness of pancreatic ductal adenocarcinoma
por: Siret, Carole, et al.
Publicado: (2018)

Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues
por: Riddick, A C P, et al.
Publicado: (2005)

Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma
por: Patard, J-J, et al.
Publicado: (2009)

Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer
por: Wong, H, et al.
Publicado: (2010)

High expression of Lin28 is associated with tumour aggressiveness and poor prognosis of patients in oesophagus cancer
por: Hamano, R, et al.
Publicado: (2012)

Construction of tissue microarrays from prostate needle biopsy specimens
por: Jhavar, S, et al.
Publicado: (2005)

TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer
por: Knight, J F, et al.
Publicado: (2008)

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study
por: Wang, L L, et al.
Publicado: (2015)

Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
por: Huang, Jiaqi, et al.
Publicado: (2016)

Absence of the DNA repair enzyme human 8-oxoguanine glycosylase is associated with an aggressive breast cancer phenotype
por: Karihtala, P, et al.
Publicado: (2012)

Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells
por: McPherson, R A C, et al.
Publicado: (2009)

EIF5A2 predicts outcome in localised invasive bladder cancer and promotes bladder cancer cell aggressiveness in vitro and in vivo
por: Wei, J-H, et al.
Publicado: (2014)

Impact of differential cyclin D1 expression and localisation in prostate cancer
por: Comstock, C E S, et al.
Publicado: (2007)

The differential effects of statins on the metastatic behaviour of prostate cancer
por: Brown, M, et al.
Publicado: (2012)

Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness
por: Weiswald, L-B, et al.
Publicado: (2009)

Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes
por: Lauvrak, S U, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_54q3q40harjeg50bd7bdvj98oa